2021 Q1 Form 10-Q Financial Statement
#000156459021024932 Filed on May 06, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $7.300M | $1.701M |
| YoY Change | 329.16% | -77.96% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $8.300M | $4.090M |
| YoY Change | 102.93% | 5.14% |
| % of Gross Profit | ||
| Research & Development | $18.40M | $20.44M |
| YoY Change | -9.94% | 114.53% |
| % of Gross Profit | ||
| Depreciation & Amortization | $159.0K | $189.0K |
| YoY Change | -15.87% | 2.72% |
| % of Gross Profit | ||
| Operating Expenses | $26.70M | $24.52M |
| YoY Change | 8.89% | 82.81% |
| Operating Profit | -$19.40M | -$22.82M |
| YoY Change | -14.98% | 300.65% |
| Interest Expense | $100.0K | $240.0K |
| YoY Change | -58.33% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$20.00K | -$437.0K |
| YoY Change | -95.42% | -170.03% |
| Pretax Income | -$19.42M | -$23.26M |
| YoY Change | -16.51% | 358.78% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$19.40M | -$23.30M |
| YoY Change | -16.74% | 356.86% |
| Net Earnings / Revenue | -265.75% | -1369.78% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$660.3K | -$1.189M |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $115.7M | $88.80M |
| YoY Change | 30.29% | -16.54% |
| Cash & Equivalents | $77.04M | $64.40M |
| Short-Term Investments | $38.60M | $24.50M |
| Other Short-Term Assets | $5.200M | $3.800M |
| YoY Change | 36.84% | -46.48% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $1.900M | |
| Other Receivables | $3.400M | |
| Total Short-Term Assets | $129.5M | $98.00M |
| YoY Change | 32.14% | -15.3% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $8.400M | $6.900M |
| YoY Change | 21.74% | -4.17% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $5.200M | $4.700M |
| YoY Change | 10.64% | 230.75% |
| Total Long-Term Assets | $13.90M | $11.90M |
| YoY Change | 16.81% | 32.96% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $129.5M | $98.00M |
| Total Long-Term Assets | $13.90M | $11.90M |
| Total Assets | $143.4M | $109.9M |
| YoY Change | 30.48% | -11.83% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.800M | $9.000M |
| YoY Change | -57.78% | 1515.8% |
| Accrued Expenses | $13.90M | $13.80M |
| YoY Change | 0.72% | 137.93% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $17.80M | $22.70M |
| YoY Change | -21.59% | 243.0% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $6.800M | $4.700M |
| YoY Change | 44.68% | 0.0% |
| Total Long-Term Liabilities | $6.800M | $4.700M |
| YoY Change | 44.68% | 0.0% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $17.80M | $22.70M |
| Total Long-Term Liabilities | $6.800M | $4.700M |
| Total Liabilities | $24.60M | $27.50M |
| YoY Change | -10.55% | 142.91% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$297.1M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $118.8M | $82.43M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $143.4M | $109.9M |
| YoY Change | 30.48% | -11.83% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$19.40M | -$23.30M |
| YoY Change | -16.74% | 356.86% |
| Depreciation, Depletion And Amortization | $159.0K | $189.0K |
| YoY Change | -15.87% | 2.72% |
| Cash From Operating Activities | -$15.48M | -$23.33M |
| YoY Change | -33.65% | 113.56% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $79.00K | |
| YoY Change | -2.47% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $3.000M | $27.86M |
| YoY Change | -89.23% | 12.57% |
| Cash From Investing Activities | $3.003M | $27.78M |
| YoY Change | -89.19% | 12.59% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $4.253M | |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 4.309M | 30.19M |
| YoY Change | -85.73% | 1825.13% |
| NET CHANGE | ||
| Cash From Operating Activities | -15.48M | -23.33M |
| Cash From Investing Activities | 3.003M | 27.78M |
| Cash From Financing Activities | 4.309M | 30.19M |
| Net Change In Cash | -8.167M | 34.63M |
| YoY Change | -123.58% | 126.14% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$15.48M | -$23.33M |
| Capital Expenditures | $79.00K | |
| Free Cash Flow | -$23.41M | |
| YoY Change | 112.7% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| spro |
Contract Term
ContractTerm
|
P2Y | ||
| CY2021Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y10M2D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y21D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y21D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y10M24D | |
| CY2021Q1 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Revenues
Revenues
|
7300000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18404000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8299000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
26703000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19403000 | |
| CY2021Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
98000 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-118000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-20000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19423000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.66 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
29414148 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-35000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19423000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-23258000 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
159000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
189000 | |
| CY2021Q1 | spro |
Non Cash Lease Cost
NonCashLeaseCost
|
199000 | |
| CY2020Q1 | spro |
Non Cash Lease Cost
NonCashLeaseCost
|
110000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2009000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1110000 | |
| CY2021Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
19000 | |
| CY2020Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-453000 | |
| CY2021Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-64000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
53000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
3218000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-869000 | |
| CY2021Q1 | spro |
Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
|
-772000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
1224000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-44000 | |
| CY2021Q1 | spro |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-195000 | |
| CY2020Q1 | spro |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-92000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15479000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23329000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
2997000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3995000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
6000000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
31850000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
79000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3003000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
27776000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4253000 | |
| CY2021Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
37000 | |
| CY2020Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
352000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
93000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
539000 | |
| CY2021Q1 | spro |
Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
|
93000 | |
| CY2020Q1 | spro |
Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
|
109000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
132040000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2009000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
4000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19423000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
118846000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
74574000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
539000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-35000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-23258000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
82427000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23300000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-297100000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19400000 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses, and the valuation of share-based awards. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has contemplated the impact of COVID-19 within its financial statements and is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. There may be changes to those estimates in future periods. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and of Significant Suppliers</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. As of <span style="color:#000000;">March 31, 2021</span>, and December 31, 2020, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
|
As of March 31, 2021, and December 31, 2020, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. | |
| CY2021Q1 | us-gaap |
Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
|
0 | |
| CY2021Q1 | spro |
Cares Act Eliminated Percentage On Limitation Of Taxable Income
CARESActEliminatedPercentageOnLimitationOfTaxableIncome
|
0.80 | |
| CY2021Q1 | spro |
Cares Act Percentage Of Adjusted Taxable Income Plus Business Interest Income
CARESActPercentageOfAdjustedTaxableIncomePlusBusinessInterestIncome
|
0.50 | |
| CY2021Q1 | spro |
Cares Act Percentage Of Limitation On Adjusted Taxable Income Plus Business Interest Income Under Tax Cut And Jobs Act2017
CARESActPercentageOfLimitationOnAdjustedTaxableIncomePlusBusinessInterestIncomeUnderTaxCutAndJobsAct2017
|
0.30 | |
| CY2021Q1 | spro |
Cares Act Percentage Of Corporate Charitable Deduction Limitation On Taxable Income
CARESActPercentageOfCorporateCharitableDeductionLimitationOnTaxableIncome
|
0.25 | |
| CY2021Q1 | spro |
Cares Act Eligible Cost Recovery Period
CARESActEligibleCostRecoveryPeriod
|
P15Y | |
| CY2021Q1 | spro |
Cares Act Percentage Of Bonus Depreciation
CARESActPercentageOfBonusDepreciation
|
1 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
3400000 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
2700000 | |
| CY2021Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
38637000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
38634000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
41703000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
6000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
41697000 | |
| CY2021Q1 | spro |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
12958000 | |
| CY2020Q4 | spro |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
12241000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.11 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
106944 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
13.41 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4583140 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
11.18 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
20727000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
4583140 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
11.18 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
20727000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2097721 | |
| CY2021Q1 | spro |
Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
|
2 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
0 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
14.57 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.38 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3682233 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.10 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
37881000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1019365 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
18.90 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
11514 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
7.58 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
13880000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
5549873 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
495396 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2009000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1110000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-23807000 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
29414148 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19557418 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.66 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.22 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19423000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-23258000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
549000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19423000 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10950140 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8698842 |
